EGFR and non-small cell lung carcinoma: Usually, ROS1 fusions de novo barely co‐occur with EGFR mutations in clinic,189 but ROS1 fusions come into sight as resistance mechanisms to EGFR–TKI therapy in EGFR‐mutant NSCLC,190 suggesting feedback or potential signaling reciprocity among ROS1 and EGFR.